Stoke Therapeutics (STOK) Long-Term Investments (2024 - 2026)

Stoke Therapeutics' Long-Term Investments history runs 3 years deep, the most recent figure standing at $67.5 million for Q1 2026.

• In Q1 2026, Long-Term Investments rose 193.54% year-over-year to $67.5 million; the TTM figure through Mar 2026 stood at $67.5 million (up 193.54% YoY), while the FY2025 annual figure was $106.3 million, up 256.29% from the prior year.
• Long-Term Investments was $67.5 million for Q1 2026 at Stoke Therapeutics, down from $106.3 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $107.3 million in Q2 2025 to a low of $23.0 million in Q1 2025.
• Historically, Long-Term Investments has averaged $63.4 million across 3 years, with a median of $67.5 million in 2026.
• Biggest YoY gain for Long-Term Investments was 256.29% in 2025; the steepest drop was 168.15% in 2025.
• A 3-year view of Long-Term Investments shows it stood at $29.8 million in 2024, then surged by 256.29% to $106.3 million in 2025, then plunged by 36.49% to $67.5 million in 2026.
• The last three Long-Term Investments figures came in at $67.5 million (Q1 2026), $106.3 million (Q4 2025), and $80.3 million (Q3 2025), per Business Quant data.